Novanta Inc. (NOVT) Stock
Key stats
- Market cap
- $4.66B
- Price / Earnings ratio
- 88.1x
- EPS (TTM)
- $1.34
- Volume
- Loading
- 52-week high
- $176.38
- 52-week low
- $98.27
Source: third-party data provider, as of November 13, 2026
Compare with NOVT
Recent news

Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
NOVT

Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
NOVT

Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Are Robots the New Normal? Bet on these ETFs to Invest in the Future
NOVT

Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
NOVT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.73
- MACD 12/26/9
- -2.74
- EMA 9 of MACD
- -0.67
- MACD histogram
- -2.06
- SMA 50
- $141.39
- Price below SMA 50
- EMA 50
- $141.83
- Price below EMA 50
- SMA 200
- $142.34
- Price below SMA 200
- EMA 200
- $138.57
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.94 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
NOVT

Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
NOVT

Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Are Robots the New Normal? Bet on these ETFs to Invest in the Future
NOVT

Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
NOVT

Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why
Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why
NOVT

Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
NOVT

Novanta Q2 Earnings Call Highlights
Novanta Q2 Earnings Call Highlights
NOVT

Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates
Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates
NOVT

Novanta Announces Financial Results for the Second Quarter 2026
Novanta Announces Financial Results for the Second Quarter 2026
NOVT

Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report?
Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report?
NOVT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Novanta Inc.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthijs Glastra | CEO & Chairman of the Board | 1969 |
| Mr. Robert J. Buckley | Chief Financial Officer | 1974 |
| Mr. Charles G. Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | 1971 |
| Mr. John Lesica | Co-Chief Operating Officer of Medical Solutions | 1976 |
| Mr. Alexander Manganiello | General Counsel & Corporate Secretary | 1967 |
| Mr. John Joseph Burke II | Chief Accounting Officer & Corporate Controller | 1982 |
| Ms. Sarah Betadam | Chief Information Officer & Chief Information Security Officer | — |
| Ms. Nissia Sabri | Senior Vice President of Corporate Development | — |
| Mr. Liam Weston | Chief Human Resources Officer | — |
| Mr. Heinrich Dreyer | Group President of Medical Solutions | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.73
- MACD 12/26/9
- -2.74
- EMA 9 of MACD
- -0.67
- MACD histogram
- -2.06
- SMA 50
- $141.39
- Price below SMA 50
- EMA 50
- $141.83
- Price below EMA 50
- SMA 200
- $142.34
- Price below SMA 200
- EMA 200
- $138.57
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.8 | +8.9 | ||||||||||
| 2022 | -20.5 | -2.3 | +9.2 | -8.9 | -6.1 | -0.1 | +29.0 | -12.5 | -12.0 | +17.5 | +12.5 | -13.5 |
| 2023 | +19.8 | -6.6 | +10.8 | -2.3 | +6.3 | +8.3 | -1.5 | -5.3 | -14.8 | -6.9 | +9.4 | +13.9 |
| 2024 | -5.9 | +9.9 | -0.3 | -9.1 | +3.4 | +1.0 | +14.8 | +7.6 | +3.4 | -2.6 | -4.2 | -9.7 |
| 2025 | -0.8 | -1.6 | -10.8 | -6.8 | +2.5 | +5.7 | -6.0 | -3.1 | -10.7 | +26.0 | -16.3 | +6.7 |
| 2026 | +21.1 | +0.1 | -16.1 | +9.4 | +24.6 | -0.7 | -12.9 | -1.4 | -1.0 | +1.5 | -15.7 |



